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Abstract
Protoporphyrin IX (PPIX) is formed from δ-aminolevulinic acid (ALA) during 
heme biosynthesis. Due to its cyclic tetrapyrrole core structure, it absorbs in the 
visible region of the electromagnetic spectrum and is thus colored. Both ALA and 
PPIX have become of great interest to neurosurgery, because in high-grade glioma, 
ALA diffuses into the tumor and is converted to PPIX. Fluorescence-guided resec-
tion (FGR) takes advantage of both the enrichment of PPIX in the tumor and its 
fluorescent properties, which enable visualization of tumor tissue. ALA-mediated 
FGR thus maximizes the extent of resection with better prognosis for patients. 
Tumor cells are able to produce porphyrins naturally or after administration of 
ALA, which is also reflected in elevated plasma fluorescence of cancer patients. 
PPIX might thus serve as a biomarker for monitoring of the tumor burden. A 
liquid chromatography-mass spectrometry (LC-MS)-based method is presented 
to quantify PPIX in blood and serum in the context of current fluorescence-based 
diagnostics. The method is able to distinguish between zinc PPIX, a component of 
red blood cells of importance in the detection of lead poisoning and iron deficiency 
anemia, and metal-free PPIX. In a proof-of-principle study, it was used to follow a 
time course of a glioblastoma patient undergoing surgery and confirmed elevated 
PPIX blood levels before ALA administration. During surgery, these blood levels 
increased about four-fold. The here developed 10 min reversed-phase LC-target MS 
method now allows patient screening with high specificity and throughput.
Keywords: protoporphyrin IX, zinc protoporphyrin IX, iron deficiency,  
lead poisoning, porphyria, biomarker, cancer, ion trap mass spectrometry,  
brain tumor, glioblastoma, blood
1. Introduction
Cyclic tetrapyrroles are biologically important molecules as they form the core 
structure of prosthetic groups such as porphyrins (e.g. heme), natural pigments like 
chlorophyll, and of vitamers (cobalamins, e.g. vitamin B12). Due to their large con-
jugated systems, they absorb in the visible region of the electromagnetic spectrum 
and are thus colored [1, 2].
Porphyrins occur naturally as metal complexes with the red pigment in blood 
cells, heme, being the best-known example. Hemes (Figure 1), the cofactors of 
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hemoproteins (e.g. hemoglobin, myoglobin) [3, 4], are complexed to iron and occur 
ubiquitously. They are critical to life, because hemoproteins are involved in the trans-
port of diatomic gases (respiration), chemical catalysis and electron transfer [5].
During heme synthesis from glycine and succinyl-CoA (Figure 2) a number of 
intermediates including δ-aminolevulinic acid (ALA) are produced until, ulti-
mately, protoporphyrin IX (PPIX) is converted to heme by insertion of a divalent 
iron (Fe (II), catalyzed by ferrochelatase) [1].
Both ALA and PPIX have become of great interest to neurosurgery, because in glio-
mas, ALA diffuses into the tumor and induces PPIX-synthesis [6]. A surgical method 
has been developed taking advantage of both the enrichment of PPIX in the tumor 
Figure 1. 
Porphyrin structures. Porphin (left), the simplest representative, and heme b (right), the prosthetic group of, 
e.g., hemoglobin, myoglobin, catalase, and cytochromeP450. Other members of the heme group (e.g. heme c in 
cytochrome C) differ slightly in the side chains. Porphyrins chelate divalent ions such as iron in heme. Due to 
their delocalized system of π-electrons they fluoresce after excitation. Different nitrogen forms in the pyrrole 
ring are labelled (red/italic, blue/bold).
Figure 2. 
Heme synthesis from succinyl-CoA to PPIX and ultimately heme. Synthesis of ALA is the rate-limiting step and 
under negative feedback control of heme (green/ dashed). A deficiency of iron supply limits heme synthesis and 
leads to PPIX accumulation. Zinc can then substitute for iron and ferrochelatase catalyzes the formation of zinc 
PPIX (red/dotted) [1].
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and its fluorescent properties, which enable visualization of the tumor area (fluores-
cence-guided resection (FGR)) [7]. Alternating between normal white light illumina-
tion and violet-blue excitation light, the vital tumor tissue can be identified by its red/
pink color during surgery; the distinction of infiltration zone and healthy brain tissue 
is improved. ALA-FGR thus maximizes the extent of tumor resection with improved 
prognosis for patients. In this context, the question arose whether or not PPIX blood 
levels could be used to monitor tumor regrowth, because the spectral characteristics 
of blood from cancer patients differ from those of control subjects [8–11].
The use of a simple analytic procedure would be cost-effective at lower strain for 
the patient. We have thus used liquid chromatography coupled to mass spectrom-
etry (LC-MS) to quantify PPIX in blood and serum and describe it in the context of 
current practice in PPIX diagnostics below.
2. Protoporphyrin IX detection
2.1 Erythrocyte protoporphyrin analysis
Erythrocyte protoporphyrin (EP) served as a diagnostic marker for lead poison-
ing and environmental lead pollution as well as for iron deficiency anemia at the 
end of the 20th century [12]. From 1972 to 1991, it was officially recommended as 
the primary screening test for childhood lead poisoning by the Center for Disease 
Control and Prevention in the United States [13–15]. For the clinical diagnosis of 
porphyrias [16], rare disorders resulting from enzyme variability in heme biosyn-
thesis, the porphyrin pattern is determined in blood, urine and faeces based on 
fluorescence techniques.
Taking advantage of the strong absorption of porphyrins in the Soret band 
(380– 430 nm) and their fluorescence, spectrophotometric and -fluorometric 
methods have been preferred for EP determination so far. The free erythrocyte 
porphyrin (FEP) test [17, 18], was, however, based on liquid-liquid extraction 
(LLE) at acidic pH, which dissociated zinc protoporphyrin (ZnPPIX) to metal-free 
PPIX during the extraction process. Thus, a sum parameter with different - and 
unknown - contributions of free PPIX and ZnPPIX was measured leading to false 
conclusions. The ratio of ZnPPIX to metal-free PPIX in erythrocytes varies, because 
in lead poisoning and iron deficiency anemia, ZnPPIX is accumulated in the blood, 
whereas in protoporphyria, the metal-free PPIX is elevated [12, 19, 20].
Hence, neutral ZnPPIX-specific LLE methods were developed, but they suffered 
from poor extraction efficiency [20, 21]. The widely applied ethyl acetate-acetic acid 
LLE method had three problems [17, 18]: First, the low extraction efficiency of PPIX 
from whole blood in comparison to the extraction from pre-diluted blood, which 
provided better precision of analysis; second, impurities in ethyl acetate influencing 
fluorescence and requiring pre-tests of reagent batches; third, the instability of PPIX 
standards prepared with deionised water. Thus, EP analysis required great attention 
to detail, because method modification, sample contamination or aging of standards 
and reagents had a great impact on analysis [22]. As a result, inter-laboratory compar-
ison of EP results was generally poor while intra-laboratory precision was good [23].
2.2 Spectrophotometry and –fluorometry
In 1977, a hematofluorometer (HF) was designed for the detection of ZnPPIX 
in a drop of whole blood without sample pretreatment, which allowed immediate, 
simple and inexpensive detection [24]. Spectrophotometric and - fluorometric 
analysis became conventional analytical practice, but the inter-laboratory 
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agreement for EP levels was still poor and standardization has not been achieved 
[25]. PPIX levels measured with the FEP-test and HF-values of ZnPPIX did not 
match [13, 23]. Problems arose as a result of the limited PPIX stability towards light 
exposure, its tendency to form molecular aggregates in aqueous solution and buffer/
solvent-dependent variation in absorbance [13]. Consequently, different values 
have been published for the molar absorptivity of PPIX, leading to discrepancies 
in the calculation of PPIX and ZnPPIX concentrations from measured absorbance 
using Beer’s Law or fluorescence emission intensity [13]. In addition, interferences 
such as bilirubin, increased hemoglobin, riboflavin, quinine as well as several drugs 
including doxorubicin or amoxycillin disturbed HF measurement; results improved 
with extended washing of erythrocytes [13, 26].
The application of dual-wavelength excitation in the HF technique [24] allowed 
the recording of background fluorescence, which then could be removed from the 
analyte spectra [27]. In 2019, it was shown that even the non-invasive measurement 
of erythrocyte ZnPPIX in children and women after childbirth was possible on the 
wet vermillion of the lower lip using this principle [28, 29].
The fluorescence method is rapid and easy to use, but it is limited by high 
background fluorescence. Complex algorithms for the processing of the obtained 
spectra are required. As fluorescence is measured as a sum parameter of all contrib-
uting analytes, results can easily be overinterpreted, especially when measuring at 
the lower limit of detection. This has to be taken into account when free PPIX is the 
target instead of ZnPPIX or the sum parameter of both. ZnPPIX is the predominant 
species of EP in circulating erythrocytes while free PPIX is only present in trace 
amounts [20, 30, 31]; the specific quantification of metal-free PPIX next to ZnPPIX 
is thus challenging.
2.3 Liquid chromatography
The absorption in the Soret band is broad and the resolution of absorption spec-
tra is low resulting in spectral overlap. Chromatographic separation of porphyrins is 
thus recommended [25]. It isolates the analyte from the sample matrix and concen-
trates it. Conclusively, the application of high-performance liquid chromatography 
(HPLC) coupled with fluorescence detection (FLD, UV-visible detection was not 
sensitive enough) [30, 32–37] and MS became highly popular. Initially performed 
thin layer chromatography assays were gradually replaced in the 1980s [36].
HPLC-FLD was demonstrated in the differentiation of porphyrin species in 
porphyria [33, 37] or lead poisoning [36]. It is now the technique of choice for 
porphyrin analysis in routine and research laboratories [28, 36]. Methods are time-
consuming with typical elution times above 20 min [34, 35]. Moreover, the analysis 
of lipophilic PPIX remains challenging, because of its comparatively low recovery. 
Porphyrins respond quite differently in HPLC and attempts to measure them all 
in a single run have been abandoned. Porphyrins also have different excretion 
patterns in the body so that the majority of laboratories determines free PPIX and 
ZnPPIX in whole blood or plasma, and other porphyrins (uroporphyrin I and III, 
coproporphyrin I and III, Figure 3) in urine, using individual HPLC-FLD methods 
optimized for each purpose [28, 33–35, 37].
Advanced column media and higher pressure LC instrumentation (ultra high-
performance (UHP) LC) further improved resolution and analysis time at lower 
solvent consumption although conventional HPLC was still widely applied. UHPLC 
from biological matrices like blood or tissue is not yet a routine technique in por-
phyrin analysis, because advanced sample preparation is required to avoid column 
contamination and clogging. Still, the use of UHPLC in conjunction with MS has 
great potential regarding sensitivity and speed of analysis [38].
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2.4 Mass spectrometry
MS detection has a number of advantages over FLD [26, 27, 39]. Both high mass 
accuracy and the possibility of breaking the analyte molecules in the gas phase and 
measuring their fragments (MS/MS) contribute to unequivocal species identifica-
tion, because complex samples can often not be fully chromatographically resolved. 
HPLC-MS was applied for the determination of porphyrin profiles in biological 
matrices [11, 39–43] using predominantly electrospray ionization (ESI) interfaces. 
Additionally, there were efforts to explore atmospheric pressure chemical ioniza-
tion [42] for the purpose.
In urine, uroporphyrin, coproporphyrin and other porphyrins were measured 
[41, 42]. As urine is a matrix with comparatively low complexity compared to blood 
and tissue, minimal sample pretreatment (acidification) was sufficient allowing 
high-throughput analysis. Providing excellent sensitivity and specificity by operat-
ing in multiple reaction monitoring mode, the presented method was superior to 
FLD [41]. Another approach in urine used porphyrin esterification followed by 
extraction and single ion monitoring MS [42].
Regarding porphyrin detection in more complex matrices, Sullivan and co-
workers [39] quantified twelve porphyrins including PPIX in liver extracts based 
on their mass, because most porphyrins co-eluted. MS/MS was not carried out. The 
method suffered from problems with peak-splitting and matrix suppression [39]. 
Furthermore, highly acidic extraction was performed so that this approach was not 
suitable for the individual determination of metal-free PPIX and ZnPPIX.
Figure 3. 
Structures of type I and III isomers of uro- and coproporphyrin in comparison to PPIX and mesoporphyrin 
(MPIX). Differences of type I and III isomers are highlighted in blue (uroporphyrin) and green 
(coproporphyrin). Differences of MPIX and PPIX structures at positions 8 and 13 are shown in grey. 
Fragmentation of PPIX in MS analysis is given in red (in the ion trap, cleavage of ethylic side chains at 
positions 8 and 13 was not observed, for MS spectra see Figure 4).
Mass Spectrometry in Life Sciences and Clinical Laboratory
6
For the investigation of porphyrins in blood, predominantly plasma or red blood 
cells were used [11, 40, 43]. In plasma, MS was applied for the quantification of 
coproporphyrin isomers for monitoring of drug interactions [43], the elucidation of 
fluorescing compounds after detection of elevated fluorescence [11], and the qualita-
tive analysis of porphyrin patterns facilitating the differential diagnosis of human 
porphyrias [40]. Despite all these efforts, no short and sensitive HPLC-MS/MS 
method for specific PPIX quantification from whole blood or serum was yet available 
although great data have been shown for less complex cell culture extracts [44, 45].
3. Protoporphyrin IX: a potential biomarker for cancer screening
More recently, besides the analysis of porphyrin metabolites [39] and profiles for 
toxicological and pharmacological applications [40–42], PPIX has been investigated 
as tumor marker for bladder, colorectal and kidney cancer [10, 11, 32]. Tumor cells 
are able to produce porphyrins naturally or after administration of ALA, which 
is also reflected in elevated plasma fluorescence of cancer patients. The spectral 
characteristics of blood from normal control subjects differ significantly from those 
of cancer patients in renal cell carcinoma, prostate cancer and colorectal adenocar-
cinoma [8–11].
PPIX analysis is, however, not straightforward in a clinical setting. Factors 
such as unrelated diseases and medication may influence the measured porphyrin 
concentration [8]. Lualdi and co-workers [11], e.g., confirmed their findings of 
enhanced plasma fluorescence in colorectal adenocarcinoma patients by HPLC 
coupled to high-resolution MS and detected mainly PPIX and coproporphyrin I. 
Ota et al. [32] applied HPLC-FLD for the determination of PPIX in plasma of blad-
der cancer patients after ALA administration. The patients showed significantly 
higher plasma PPIX concentrations compared to healthy adults. It was extrapolated 
that the accumulation of PPIX in cancer cells is common to almost all types of 
cancer [8–10] and that the specific measurement of PPIX is advantageous for cancer 
screening [32].
A further application of PPIX is above-mentioned photodynamic diagnosis, 
where PPIX is applied as an intraoperative marker especially for brain tumors. 
Using ALA-induced PPIX-fluorescence in tissue during surgery of high-grade 
glioma, the resection is more complete and the patients have a higher 6-month pro-
gression-free survival compared to those without FGR [7]. Unfortunately, due to 
the infiltrative growth of these tumors, complete tumor resection is still impossible 
and tumors can recur. Clinically, diagnosis of high-grade glioma and glioblastoma 
multiforme (GBM) as well as their recurrence requires multidisciplinary strategies 
such as contrast enhancement magnetic resonance imaging, computer tomography 
and biopsy [6, 7, 46, 47]. Therefore, a sensitive and cost-effective method for tumor 
monitoring is highly desirable supporting early diagnosis and treatment of GBM as 
well as better prognosis for patients. So far, the survival prognosis for GBM patients 
is one of the lowest in modern day oncology [47]. As PPIX is an approved marker 
for GBM tissue in ALA-FGR, here, the hypothesis was tested if it could also be a 
blood biomarker for GBM screening and diagnosis.
4. PPIX quantification
For the detection of PPIX in whole blood or serum, we developed an HPLC-MS 
method using an HP1100 HPLC (Agilent, Waldbronn, Germany) coupled to an 
Esquire 3000 ion trap mass spectrometer (Bruker Corp., Bremen, Germany). 
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Mesoporphyrin (MPIX) (Figure 3) was chosen as internal standard (IS), because it 
provided high structural similarity to PPIX and isotope labeled standards for PPIX 
were not available. Distinction of PPIX from ZnPPIX was possible during sample 
preparation. The method described below allowed the quantification of metal-free 
PPIX in whole blood, the determination of endogenous PPIX in serum and the 
measurement of endogenous ZnPPIX in whole blood (200 μl, respectively).
4.1 Sample preparation
PPIX LLE extraction from serum and whole blood was achieved with only 
water and acetonitrile (ACN). Hemolysis with water was crucial for good recovery 
as observed by others working with pre-dilution [22]. It was followed by protein 
precipitation with ACN; concomitant porphyrins were extracted into the superna-
tant [48], which was further purified using anionic-exchange solid phase extraction 
(SPE) cartridges. The extracts of whole blood and serum had a pH 8–9 so that PPIX, 
ZnPPIX and MPIX had deprotonated propionic acid side chains and were negatively 
charged. No conversion of ZnPPIX into metal-free PPIX was observed before loading 
the extracts onto the SPE cartridge. All three porphyrins were retained on the car-
tridge presenting quaternary ammonium groups. MPIX and PPIX were eluted using 
ACN containing 2% formic acid (FA), ZnPPIX with increased FA content (20%). No 
elution or hydrolysis of ZnPPIX was detected at 2% FA; only metal-free PPIX was 
seen in the first eluate. The higher percentage of FA in the second step caused the 
acidic release of the Zn2+ ion. ZnPPIX was thus detected as metal-free PPIX.
4.2 Gas phase fragmentation
As already demonstrated in the literature for other porphyrins [40], PPIX ion-
izes as singly charged [M+H]+ species (m/z 563.3) in ESI-MS. MS/MS fragmentation 
preferentially occurs on the side chains (Figure 3). The spectra in Figure 4 illustrate 
the stepwise fragmentation of PPIX from preselected precursor ions in subsequent 
MS/MS and MS/MS/MS experiments in the ion trap. The abundant loss of an etha-
noic acid substituent (-CH2COOH; 563-59 u) results in a fragment ion at m/z 504.3 
that is used as precursor for MS3 fragmentation which then generates further side 
chain losses (-CH3, 15/30 u; -COOH, 45 u; -CH2COOH, 59 u; -CH2CH2COOH, 73 u).
For selected compounds, it was discussed that even-electron ions generated 
in the ESI source can produce radical cations with odd-electrons by hemolytic 
cleavage. The most common process in radical fragmentation is the elimination of 
a methyl group as proposed for flavonoids, antraquinones and terpenoids [49]. It 
was shown that the radical elimination of the methyl group is a low energy process 
in flavonoids. The loss of 59 u by radical cleavage was also already described for 
FePPIX in previous studies on metalloporphyrins and other compounds with 
extended π-electron systems [50–52].
The fragmentation of MPIX is similar to PPIX. MPIX has two saturated ethyl 
side chains at positions 8 and 13 (Figure 3) so that precursor and fragment ions 
differ by four mass units in comparison to PPIX.
ZnPPIX was measured in MS/MS mode as it showed lower ionization effi-
ciency than MPIX and PPIX. The time-segmented method switched from MS/
MS mode for ZnPPIX detection to MS3 mode for MPIX and PPIX measurement. 
This approach proved advantageous in comparison to continuous MS/MS and MS3 
switching for porphyrins and significantly increased sensitivity. In comparison to 
the ion traces of matrix-free porphyrin standard solution, the background signal 
was about five times higher in whole blood extracts, but that did not hamper detec-
tion with the specific MS3 method.
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4.3 Chromatography
HPLC separation of PPIX was not straightforward, because of its high lipophilic 
nature. Problems included low resolution on capillary C8 LC and high carry-over 
on endcapped C18 phase. The low flow rate of capillary LC (5 μl/min) was also 
disadvantageous for porphyrin separation. Analytical LC with its higher flow 
rate (300 μl/min) in conjunction with a semi-porous C18 column media and an 
almost isocratic gradient allowed much more efficient operation at great resolu-
tion. Figure 5 shows the separation of a standard solution of ZnPPIX (10 pmol on 
column), MPIX and PPIX (5 pmol on column each).
4.4 Procedure
All experiments were performed in accordance with the declaration of Helsinki 
and by approval of the Ethics Committee of the Ärztekammer Westfalen-Lippe 
(2017-169-f-S).
Figure 4. 
Fragmentation of PPIX in the ion trap. A: [M+H]+ ion of PPIX at m/z 563.3 in full scan mode. B: MS/MS 
spectrum of precursor ion at m/z 563.3. The loss of the ethanoic acid side chain (59 u) is dominant. C: MS3 
spectrum for two-step fragmentation (m/z 563.3 -> m/z 504.3). The major ions result from side chain cleavage 
(red arrows, for structure see Figure 3).
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PPIX was obtained from Enzo life sciences GmbH (Lörrach, Germany), MPIX 
and ZnPPIX from Merck KGaA (Darmstadt, Germany). ACN, water, FA and 
methanol (MeOH) were all LC-MS grade and purchased from Merck KGaA as were 
ammonium hydroxide solution and dimethyl sulfoxide (DMSO). SPE cartridges 
came from Restek GmbH (Bad Homburg, Germany).
For drying of samples, a SpeedVac system (Savant SPD 111V SpeedVac con-
centrator with vapor trap Savant RVT 5105) was used (Thermo Fisher Scientific, 
Schwerte, Germany). For centrifugation, a Universal 320R Hettich centrifuge 
(Tuttlingen, Germany) was utilized.
Hemolysis of 200 μl whole blood or serum was performed by adding 800 μl of 
water and shaking at room temperature for 1 h. Protein precipitation and porphyrin 
extraction was achieved by adding 2 ml of ACN, shaking at room temperature for 
1 h and centrifuging at 14.000 rcf at 20 °C for 30 min. The clear supernatant was 
then transferred to an SPE cartridge, which was treated as described in Table 1. 
The 1st and 2nd eluates were dried and finally reconstituted in 15 μl DMSO for 
HPLC-MS (for parameters see Tables 2 and 3).
Raw data were converted using the msConvert toolkit from ProteoWizard 
software (version 3; [53]). MPIX and PPIX were quantified using the total areas for 
the three most abundant fragment ions in MS3 mode (MPIX: extracted ion chro-
matogram (EIC) m/z 449.3, 479.3, 493.3; PPIX: m/z 445.3, 459.3, 489.3) and Skyline 
software (version 20.1; [54]).
Figure 5. 
Extracted ion chromatogram (EIC) of porphyrin standard (ZnPPIX m/z 565.2; MPIX m/z 449.3; PPIX m/z 445.3) 
as detected with a time-segmented method on the Esquire 3000 ion trap (for parameters see 4.4).
Mass Spectrometry in Life Sciences and Clinical Laboratory
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LC-Parameter
Column Poroshell C18 (2.7 μm, 2.1 mm i.d.) with guard column
Flow 0.3 ml/min
Solvent A 95% water/4.9% ACN/0.1% FA
Solvent B 95% ACN/4.9% water/0.1% FA






Injection volume 10 μl
MS-Parameter ESI (+)
Capillary −4.5 kV
End plate −500 V
Nebulizer 30.0 psi
Dry gas 9 l/min
Dry temperature 320°C
Scan range 400–700 m/z
Table 2. 
HPLC-MS parameter for porphyrin detection.
Step Solvent
Cartridge conditioning 2 ml ACN
Equilibration 2 ml water
Sample load porphyrin extract (~3 ml)
1st Wash 2 ml 5% ammonium hydroxide solution
2nd Wash 2 ml MeOH
1st Elution 2 ml ACN with 2% FA
2nd Elution 2 ml ACN with 20% FA
Table 1. 
Protocol for the purification of neutral porphyrin extract with SPE cartridges.
Analyte Time [min] Mode Isolation m/z Fragmentation amplitude
ZnPPIX 3.4–4.3 MS/MS 625.2 ± 5.0 0.43
MPIX 4.3–5.3 MS/MS 567.3 ± 2.0 0.90
MS3 508.3 ± 2.0 0.70
PPIX 5.3–7.0 MS/MS 563.3 ± 2.0 0.85
MS3 504.3 ± 2.0 0.70
Table 3. 
Parameters for MS/MS detection of ZnPPIX and MS3 detection of PPIX and MPIX.
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Calibration was performed in the relevant matrix (whole blood of a healthy 
volunteer) using 500 fmol to 50 pmol PPIX spikes and 500 fmol/μl MPIX 
(Figure 6). The contribution of native PPIX was determined in an aliquot spiked 
with MPIX only.
5. Measurement of clinical samples
Samples from a patient harboring a GBM and undergoing surgery were  collected 
at different time points before, during and after surgery. The first sample was 
obtained 1 h prior to ALA administration for the determination of the basic free 
PPIX level, the following samples were collected 5 and 7 h after ALA administration. 
Whole blood samples were refrigerated and stored in the dark. Porphyrins were 
extracted in triplicate using 200 μl of whole blood for each experiment.
Figure 7 shows the results. The level prior to ALA administration was measured 
twice (two different extractions from the same blood sample) and was 33.9 ±0.4 and 
34.9 ± 1.9 pmol PPIX/ml whole blood. After ALA administration, the PPIX level 
rose about four-fold to 100.9 ± 2.7 and 114.4 ± 11.4 pmol PPIX/ml, respectively, at 
Figure 6. 
Calibration curve for PPIX spiked into the whole blood of a healthy volunteer. MPIX (IS) was spiked at 
500 fmol/μl. Five replicate injections (10 μl each) were run.
Figure 7. 
Overlay of three EIC traces (MPIX m/z 449.3; PPIX m/z 445.3) from measurement of whole blood from a 
GBM patient taken at different time points. The red line shows a sample prior to ALA administration, whereas 
the blue and black lines mark the samples 5 and 7 h after ALA administration.
Mass Spectrometry in Life Sciences and Clinical Laboratory
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the later time points. For comparison, PPIX levels were determined in two healthy 
volunteers without ALA administration. They reached only about a third of the 
pre-surgery level of the patient (11.0 ± 0.7 and 12.1 ± 0.4 pmol PPIX/ml). These 
observations are summarized in Figure 8. So far, having tested one patient only, the 
results support the hypotheses of elevated PPIX in the circulation as discussed in the 
literature for other types of cancer [8–11, 32] and the timely and dramatic increase 
after ALA administration. An extended study involving more probands is planned.
6. Conclusion
MS has the huge advantage over fluorescence-based porphyrin detection that it 
can pinpoint the individual molecules by their mass and, adding to the specificity, 
by their fragmentation pattern, which can be generated in the mass spectrometer. 
Ambiguities as known from fluorescence spectroscopy due to varying or over-
lapping absorbance maxima and extinction coefficients or fluorescing matrix 
interferences do not occur; background corrections with complex spectral fitting 
algorithms are not necessary.
A LC-MS method for the quantification of metal-free PPIX in whole blood 
was developed. It is short (10 min) and robust (analytical LC, ion trap MS) and 
provides the necessary specificity and sensitivity. ZnPPIX, MPIX and PPIX can be 
baseline resolved without the carryover problems observed earlier. The LLE sample 
preparation provides high extract purity with good recovery. Importantly, ZnPPIX 
and PPIX can be properly distinguished during SPE clean-up. Matrix effects which 
would negatively affect HPLC-MS analysis were not observed.
The method is applicable to serum in the same manner, however, serum and 
plasma PPIX levels are much lower than those of whole blood. Unfortunately, the 
values reported in the literature lack confidence (Table 4). There is no reference 
range for PPIX in serum or whole blood for healthy individuals. PPIX plasma 
concentrations in healthy subjects after ALA administration were low and erratic, 
ranging from below the limit of quantification to hundreds of nmol/l [32, 55, 56]. 
Often, PPIX was not detected in plasma samples at all [55]. In serum, PPIX levels 
are lower still, even after ALA administration.
Our results indicate the same extract purity for spiked PPIX extracted from 
serum as from whole blood. The recovery of PPIX was even slightly better. 
Figure 8. 
Time series of a GBM patient with ALA administration at 9 am, illustrated by blue bar and blue points. The 
pre-ALA PPIX level was confirmed in the same blood sample (orange triangle). PPIX levels in blood of healthy 
volunteers were determined for comparison (green crosses).
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Nevertheless, quantification requires more effort, because only trace amounts of 
endogenous PPIX were detected in sera of healthy adults so far.
In proof-of-principle experiments the LC-MS method was applied to blood 
samples from a GBM patient, which confirmed both the elevated PPIX levels in the 
blood of GBM patients and the increase following ALA administration. The method 
is now ready for patient screening. Additional resolution and sensitivity for high 
throughput analysis could be achieved with instrumentation such as a triple quad-
rupole mass spectrometer, if desired.
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PPIX in plasma (HPLC-FLD) [nmol/l] Reference
Protoporphyria 2-15 [56]
Healthy adults after ALA administration 0.2-2.8 [32]
17.8–444.3 [55]
Table 4. 
Reported PPIX levels in plasma, measured with HPLC-FLD.
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